Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with Darbepoetin alfa in patient on hemodialysis

Yaeirim Kim1, Su-Kil Park2, Won Yong Cho3, Kwon Wook Joo4, Sug Kyun Shin5, Dae Joong Kim6, Yong-Lim Kim7, Sung Hyun Sohn8, Wookyung Chung9, Kwang Young Lee10, Sung Kwang Park11, Joong Kyung Kim12, Soo Wan Kim13, Duk-Hee Kang14, Jin Kuk Kim15, Jin Seok Jeon16, Kang Wook Lee17, Chang Hwa Lee18, Dong-Jin Oh19, Won Suk An20, Jong Soo Lee21, Gun Woo Kang22, Jun-young Do23, Jung Pyo Lee24, Kyubok Jin1

1Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea
2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Internal Medicine, Korea University Medical College, Seoul, Korea
4Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
5Department of Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi-do, Korea
6Department of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, Korea
7Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea
8Department of Internal Medicine, Suyeong Hanseu Hospital, Busan, Korea
9Department of Internal Medicine, Gil Medical Center, Gachon University of Medicine and Science, Korea
10Department of Internal Medicine, Presbyterian Medical Center, Jeonju, Korea
11Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea
12Department of Internal Medicine, Bong Seng Memorial Hospital, Busan, Korea
13Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
14Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea
15Department of Internal Medicine, Soochunhyang University College of Medicine, Bucheon, Korea
16Department of Internal Medicine, Soochunhyang University College of Medicine, Seoul, Korea
17Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea
18Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea
19Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea
20Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea
21Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea
22Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
23Department of Internal Medicine, Yeungnam University School of Medicine, Daegu, Korea
24Department of Internal Medicine, Seoul National University College of Medicine and SMG-SNU Boramae Medical Center, Seoul, Korea

Objectives: Anemia is critical problem which is caused by deficiency of endogenous erythropoietin (EPO) synthesis in patient on dialysis. Darbepoetin-alfa is a useful EPO with long elimination half-life. Herein, we aim to evaluate the efficacy and safety of intravenous CKD-11101 (biosimilar darbepoetin-alfa) compared with darbepoetin-alfa in patients undergoing hemodialysis.

Methods: The study group composed with 24 different institutes was divided by randomized, double-blinded, and prospectively. Follow-up duration was 24 weeks which was consisted with 20 weeks of maintenance and 4 weeks of evaluation period. All patients underwent the stabilization period to achieve target baseline hemoglobin (Hb) as 10-12 g/dL before randomization. After randomization, patients received EPO by weekly or biweekly with adjusted dose following the
permitted rule of darbepoetin alfa. First, we compared the efficacy of CKD-11101 to darbepoetin-alfa. Secondly, we investigated the safety of CKD-11101.

Results: A total of 403 patients were randomized to two different groups during June 2015 and June 2017. Among randomized populations, 78 (19.35%) were dropped-out with major infraction or side effect, 325 (80.65%) patients completed the investigation. The average administered dose of EPO was not different in both groups; 74.90 ± 56.85 mcg and 61.96 ± 43.51 mcg in CKD-11101 and darbepoetin-alfa, respectively. During the study period, the percentage of patients with targeted Hb was 19.44% (28/144), and 20.95% (31/148) with CKD-11101 and darbepoetin-alfa, respectively (p = 0.750). There was no difference in rate of patients need to be changed the dose; 95.83% (138/144) and 93.24% (138/148) with CKD-11101 and darbepoetin-alfa (p = 0.331). There was only one patient who needed to be transfused in each group.

Conclusions: The difference in change of the level of Hb, dose of EPO, and achievement rate to target Hb during study period was comparable between two groups. CKD-11101 has an equivalent therapeutic efficacy compared with the darbepoetin-alfa in patient undergoing hemodialysis.